Title: 1, 2, 4-OXADIAZOLES AZETIDINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS

Abstract: The present invention relates to 1,2,4-oxadiazoles azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
1, 2, 4-OXADIAZOLES AZETIDINE DERIVATIVES AS
SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS

By inventors: Janet A. Takeuchi, Ling Li, Ken Chow and Wha-Bin Im

RELATED APPLICATION

This application claims the benefit of United States Provisional Patent Application Serial No. 61/709,863, filed October 4, 2012, the disclosure of which is hereby incorporated in its entirety herein by reference.

FIELD OF THE INVENTION

The present invention relates to 1,2,4-oxadiazoles azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with sphingosine-1-phosphate (S1P) receptor modulation.

BACKGROUND OF THE INVENTION

Sphingosine-1 phosphate is stored in relatively high concentrations in human platelets, which lack the enzymes responsible for its catabolism, and it is released into the blood stream upon activation of physiological stimuli, such as growth factors, cytokines, and receptor agonists and antigens. It may also have a critical role in platelet aggregation and thrombosis and could aggravate cardiovascular diseases. On the other hand the relatively high concentration of the metabolite in high-density lipoproteins (HDL) may have beneficial implications for atherogenesis. For example, there are recent suggestions that sphingosine-1-phosphate, together with other lysolipids such as sphingosylphosphorylcholine and lysosulfatide, are responsible for the beneficial clinical effects of HDL by stimulating the production of the potent antiatherogenic signaling molecule nitric oxide by the vascular endothelium. In addition, like lysophosphatidic acid, it is a marker for certain types of cancer, and there is evidence that its role in cell division or proliferation may have an influence on the development of cancers. These are currently topics that are attracting great interest amongst medical researchers, and
the potential for therapeutic intervention in sphingosine-1-phosphate metabolism is under active investigation.

**SUMMARY OF THE INVENTION**

We have now discovered a group of novel compounds which are potent and selective sphingosine-1-phosphate modulators. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors. The term "modulator" as used herein, includes but is not limited to: receptor agonist, antagonist, inverse agonist, inverse antagonist, partial agonist, partial antagonist.

This invention describes compounds of Formula I, which have sphingosine-1-phosphate receptor biological activity. The compounds in accordance with the present invention are thus of use in medicine, for example in the treatment of humans with diseases and conditions that are alleviated by S1P modulation.

In one aspect, the invention provides a compound having Formula I or a pharmaceutically acceptable salt thereof or individual enantiomers, diastereoisomers, tautomers, zwitterions and pharmaceutically acceptable salts thereof:

![Formula I](image)

wherein:
R is substituted or unsubstituted C\textsubscript{6-10} aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted C\textsubscript{5-8} cycloalkyl, substituted or unsubstituted C\textsubscript{5-8} cycloalkenyl or hydrogen;

R\textsuperscript{2} is hydrogen, -OCl\textsubscript{3} alkyl or substituted or unsubstituted C\textsubscript{1-3} alkyl;

R\textsuperscript{3} is hydrogen, halogen, substituted or unsubstituted C\textsubscript{1-3} alkyl, C(0)R\textsuperscript{7} or hydroxyl;

R\textsuperscript{4} is hydrogen, halogen, substituted or unsubstituted C\textsubscript{1-3} alkyl, C(0)R\textsuperscript{7} or hydroxyl;

R\textsuperscript{5} is hydrogen, halogen, substituted or unsubstituted C\textsubscript{1-3} alkyl, C(0)R\textsuperscript{7}, hydroxyl or substituted or unsubstituted heterocycle;

R\textsuperscript{6} is hydrogen, halogen, substituted or unsubstituted C\textsubscript{1-3} alkyl, C(0)R\textsuperscript{7}, hydroxyl or substituted or unsubstituted heterocycle;

R\textsuperscript{7} is hydrogen, -OR\textsuperscript{8} or substituted or unsubstituted C\textsubscript{1-3} alkyl;

R\textsuperscript{8} is H or Cl\textsubscript{3} alkyl;

a is 2 or 3;

b is 1, 2 or 3; and

c is 1, 2, 3, 4, 5 or 6.

The term "alkyl", as used herein, refers to saturated, monovalent or divalent hydrocarbon moieties having linear or branched moieties or combinations thereof and containing 1 to 3 carbon atoms. One methylene (-CH\textsubscript{2}-) group, of the alkyl can be replaced by oxygen, sulfur, sulfoxide, -NH-, carbonyl, carboxyl, sulfonyl, or by a divalent C\textsubscript{5-8} cycloalkyl. Alkyl groups can be substituted by halogen, hydroxyl, cycloalkyl, amino, non-aromatic heterocycles, carboxylic acid, phosphonic acid groups, sulphonic acid groups, phosphoric acid.

The term "cycloalkyl", as used herein, refers to a monovalent or divalent group of 5 to 8 carbon atoms derived from a saturated cyclic hydrocarbon. Cycloalkyl groups can be monocyclic or polycyclic. Cycloalkyl can be substituted by 1 to 3 C\textsubscript{1-3} alkyl groups or 1 or 2 halogens.

The term "cycloalkenyl", as used herein, refers to a monovalent or divalent group of 5 to 8 carbon atoms derived from a saturated cycloalkyl having one double bond.

Cycloalkenyl groups can be monocyclic or polycyclic. Cycloalkenyl groups can be substituted by 1 to 3 C\textsubscript{1-3} alkyl groups or 1 or 2 halogens.

The term "halogen", as used herein, refers to an atom of chlorine, bromine, fluorine, iodine.
The term "heterocycle" as used herein, refers to a 3 to 10 membered ring, which can be aromatic or non-aromatic, saturated or non-saturated, containing at least one heteroatom selected from O or N or S or combinations of at least two thereof, interrupting the carbocyclic ring structure. The heterocyclic ring can be saturated or non-saturated. The heterocyclic ring can be interrupted by a C=O; the S heteroatom can be oxidized. Heterocycles can be monocyclic or polycyclic. Heterocyclic ring moieties can be substituted by hydroxyl, 1 to 2 C1-3 alkyl or 1 to 2 halogens.

The term "aryl" as used herein, refers to an organic moiety derived from an aromatic hydrocarbon consisting of a ring containing 6 to 10 carbon atoms by removal of one hydrogen, which can be substituted by 1 to 3 halogen atoms or by 1 to 2 C1-3 alkyl groups.

The term "hydroxyl" as used herein, represents a group of formula "-OH".
The term "carbonyl" as used herein, represents a group of formula "-C(O)".
The term "carboxyl" as used herein, represents a group of formula "-C(0)O".
The term "sulfonyl" as used herein, represents a group of formula "-SO2".
The term "sulfate" as used herein, represents a group of formula "-0-S(0)2-0-".
The term "carboxylic acid" as used herein, represents a group of formula "-C(0)OH".
The term "sulfoxide" as used herein, represents a group of formula "-S=O".
The term "phosphonic acid" as used herein, represents a group of formula "-P(0)(OH)2".
The term "phosphoric acid" as used herein, represents a group of formula "-(0)P(0)(OH)2".
The term "sulphonic acid" as used herein, represents a group of formula "-S(0)2OH".
The formula "H1 " as used herein, represents a hydrogen atom.
The formula "O" as used herein, represents an oxygen atom.
The formula "N" as used herein, represents a nitrogen atom.
The formula "S" as used herein, represents a sulfur atom.

1-{4-[5-(4-Phenylbutyl)-1 ,2,4-oxadiazol-3-yl]benzyl}azetidine-3-carboxylic acid is a compound of the invention.
Some compounds of Formula I and some of their intermediates have at least one stereogenic center in their structure. This stereogenic center may be present in an R or S configuration, said R and S notation is used in correspondence with the rules described in Pure Appl. Chem. (1976), 45, 11-13.

The term "pharmacologically acceptable salts" refers to salts or complexes that retain the desired biological activity of the above identified compounds and exhibit minimal or no undesired toxicological effects. The "pharmacologically acceptable salts" according to the invention include therapeutically active, non-toxic base or acid salt forms, which the compounds of Formula I are able to form.

The acid addition salt form of a compound of Formula I that occurs in its free form as a base can be obtained by treating the free base with an appropriate acid such as an inorganic acid, such as for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; or an organic acid such as for example, acetic, hydroxyacetic, propanoic, lactic, pyruvic, malonic, fumaric acid, maleic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, citric, methylsulfonic, ethanesulfonic, benzenesulfonic, formic and the like (Handbook of Pharmaceutical Salts, P.Heinrich Stahal& Camille G. Wermuth (Eds), Verlag Helvetica Chimica Acta- Zurich, 2002, 329-345).

The base addition salt form of a compound of Formula I that occurs in its acid form can be obtained by treating the acid with an appropriate base such as an inorganic base, for example, sodium hydroxide, magnesium hydroxide, potassium hydroxide, calcium hydroxide, ammonia and the like; or an organic base such as for example, L-Arginine, ethanolamine, betaine, benzathine, morpholine and the like. (Handbook of Pharmaceutical Salts, P.Heinrich Stahal& Camille G. Wermuth (Eds), Verlag Helvetica Chimica Acta- Zurich, 2002, 329-345).

In another embodiment, there are provided pharmaceutical compositions including at least one compound of the invention in a pharmaceutically acceptable carrier.

The compounds of the invention are indicated for use in treating or preventing conditions in which there is likely to be a component involving the sphingosine-1-phosphate receptors. In a further embodiment of the invention, there are provided methods for treating disorders associated with modulation of sphingosine-1-phosphate receptors. Such methods can be performed, for example, by administering to a subject
in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one compound of the invention. These compounds are useful for the treatment of mammals, including humans, with a range of conditions and diseases that are alleviated by S1P modulation: not limited to the treatment of diabetic retinopathy, other retinal degenerative conditions, dry eye, angiogenesis and wounds.

Therapeutic utilities of S1P modulators are ocular diseases, such as but not limited to: wet and dry age-related macular degeneration, diabetic retinopathy, angiogenesis inhibition, retinopathy of prematurity, retinal edema, geographic atrophy, glaucomatous optic neuropathy, chorioretinopathy, hypertensive retinopathy, ocular ischemic syndrome, prevention of inflammation-induced fibrosis in the back of the eye, various ocular inflammatory diseases including uveitis, scleritis, keratitis, and retinal vasculitis; or systemic vascular barrier related diseases such as but not limited to: various inflammatory diseases, including acute lung injury, its prevention, sepsis, tumor metastasis, atherosclerosis, pulmonary edemas, and ventilation-induced lung injury; or autoimmune diseases and immunosuppression such as but not limited to: rheumatoid arthritis, Crohn’s disease, Graves’ disease, inflammatory bowel disease, multiple sclerosis, Myasthenia gravis, Psoriasis, ulcerative colitis, antoimmune uveitis, renal ischemia/perfusion injury, contact hypersensitivity, atopic dermititis, and organ transplantation; or allergies and other inflammatory diseases such as but not limited to: urticaria, bronchial asthma, and other airway inflammations including pulmonary emphysema and chronic obstructive pulmonary diseases; or cardiac protection such as but not limited to: ischemia reperfusion injury and atherosclerosis; or wound healing such as but not limited to: scar-free healing of wounds from cosmetic skin surgery, ocular surgery, GI surgery, general surgery, oral injuries, various mechanical, heat and burn injuries, prevention and treatment of photoaging and skin ageing, and prevention of radiation-induced injuries; or bone formation such as but not limited to: treatment of osteoporosis and various bone fractures including hip and ankles; or anti-nociceptive activity such as but not limited to: visceral pain, pain associated with diabetic neuropathy, rheumatoid arthritis, chronic knee and joint pain, tendonitis, osteoarthritis, neuropathic pains; or central nervous system neuronal activity in Alzheimer’s disease, age-related neuronal injuries; or in organ transplant such as renal, corneal, cardiac or adipose tissue transplant.

In still another embodiment of the invention, there are provided methods for treating disorders associated with modulation of sphingosine-1-phosphate receptors.
Such methods can be performed, for example, by administering to a subject in need thereof a therapeutically effective amount of at least one compound of the invention, or any combination thereof, or pharmaceutically acceptable salts, individual enantiomers and diastereomers thereof.

The present invention concerns the use of a compound of Formula I or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of ocular disease, wet and dry age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, retinal edema, geographic atrophy, angiogenesis inhibition, glaucomatous optic neuropathy, chorioretinopathy, hypertensive retinopathy, ocular ischemic syndrome, prevention of inflammation-induced fibrosis in the back of the eye, various ocular inflammatory diseases including uveitis, scleritis, keratitis, and retinal vasculitis; or systemic vascular barrier related diseases, various inflammatory diseases, including acute lung injury, its prevention, sepsis, tumor metastasis, atherosclerosis, pulmonary edemas, and ventilation-induced lung injury; or autoimmune diseases and immunosuppression, rheumatoid arthritis, Crohn's disease, Graves' disease, inflammatory bowel disease, multiple sclerosis, Myasthenia gravis, Psoriasis, ulcerative colitis, autoimmune uveitis, renal ischemia/perfusion injury, contact hypersensitivity, atopic dermatitis, and organ transplantation; or allergies and other inflammatory diseases, urticaria, bronchial asthma, and other airway inflammations including pulmonary emphysema and chronic obstructive pulmonary diseases; or cardiac protection, ischemia reperfusion injury and atherosclerosis; or wound healing, scar-free healing of wounds from cosmetic skin surgery, ocular surgery, GI surgery, general surgery, oral injuries, various mechanical, heat and burn injuries, prevention and treatment of photoaging and skin ageing, and prevention of radiation-induced injuries; or bone formation, treatment of osteoporosis and various bone fractures including hip and ankles; or anti-nociceptive activity, visceral pain, pain associated with diabetic neuropathy, rheumatoid arthritis, chronic knee and joint pain, tendonitis, osteoarthritis, neuropathic pains; or central nervous system neuronal activity in Alzheimer's disease, age-related neuronal injuries; or in organ transplant such as renal, corneal, cardiac or adipose tissue transplant.

The actual amount of the compound to be administered in any given case will be determined by a physician taking into account the relevant circumstances, such as the
severity of the condition, the age and weight of the patient, the patient's general physical condition, the cause of the condition, and the route of administration.

The patient will be administered the compound orally in any acceptable form, such as a tablet, liquid, capsule, powder and the like, or other routes may be desirable or necessary, particularly if the patient suffers from nausea. Such other routes may include, without exception, transdermal, parenteral, subcutaneous, intranasal, via an implant stent, intrathecal, intravitreal, topical to the eye, back to the eye, intramuscular, intravenous, and intrarectal modes of delivery. Additionally, the formulations may be designed to delay release of the active compound over a given period of time, or to carefully control the amount of drug released at a given time during the course of therapy.

In another embodiment of the invention, there are provided pharmaceutical compositions including at least one compound of the invention in a pharmaceutically acceptable carrier thereof. The phrase "pharmaceutically acceptable" means the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Pharmaceutical compositions of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a patch, a micelle, a liposome, and the like, wherein the resulting composition contains one or more compounds of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications. Invention compounds may be combined, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextran, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. Invention compounds are included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or disease condition.

Pharmaceutical compositions containing invention compounds may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or
Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of a sweetening agent such as sucrose, lactose, or saccharin, flavoring agents such as peppermint, oil of wintergreen or cherry, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets containing invention compounds in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods. The excipients used may be, for example, (1) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents such as corn starch, potato starch or alginic acid; (3) binding agents such as gum tragacanth, corn starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.

In some cases, formulations for oral use may be in the form of hard gelatin capsules wherein the invention compounds are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the invention compounds are mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.

The pharmaceutical compositions may be in the form of a sterile injectable suspension. This suspension may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides, fatty acids (including oleic acid), naturally occurring vegetable oils like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or synthetic fatty vehicles like ethyl oleate or the like. Buffers, preservatives, antioxidants, and the like can be incorporated as required.

Pharmaceutical compositions containing invention compounds may be in a form suitable for topical use, for example, as oily suspensions, as solutions or suspensions in
aqueous liquids or nonaqueous liquids, or as oil-in-water or water-in-oil liquid emulsions. Pharmaceutical compositions may be prepared by combining a therapeutically effective amount of at least one compound according to the present invention, or a pharmaceutically acceptable salt thereof, as an active ingredient with conventional ophthalmically acceptable pharmaceutical excipients and by preparation of unit dosage suitable for topical ocular use. The therapeutically efficient amount typically is between about 0.0001 and about 5% (w/v), preferably about 0.001 to about 2.0% (w/v) in liquid formulations.

For ophthalmic application, preferably solutions are prepared using a physiological saline solution as a major vehicle. The pH of such ophthalmic solutions should preferably be maintained between 4.5 and 8.0 with an appropriate buffer system, a neutral pH being preferred but not essential. The formulations may also contain conventional pharmaceutically acceptable preservatives, stabilizers and surfactants. Preferred preservatives that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate and phenylmercuric nitrate. A preferred surfactant is, for example, Tween 80. Likewise, various preferred vehicles may be used in the ophthalmic preparations of the present invention. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose cyclodextrin and purified water.

Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.

Various buffers and means for adjusting pH may be used so long as the resulting preparation is ophthalmically acceptable. Accordingly, buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.

In a similar manner an ophthalmically acceptable antioxidant for use in the present invention includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.

Other excipient components which may be included in the ophthalmic preparations are chelating agents. The preferred chelating agent is edentate disodium, although other chelating agents may also be used in place of or in conjunction with it.
The ingredients are usually used in the following amounts:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Amount ( % w/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>active ingredient</td>
<td>about 0.001-5</td>
</tr>
<tr>
<td>preservative</td>
<td>0-0.10</td>
</tr>
<tr>
<td>vehicle</td>
<td>0-40</td>
</tr>
<tr>
<td>tonicity adjustor</td>
<td>0-10</td>
</tr>
<tr>
<td>buffer</td>
<td>0.01-10</td>
</tr>
<tr>
<td>pH adjustor</td>
<td>q.s. pH 4.5-7.8</td>
</tr>
<tr>
<td>antioxidant</td>
<td>as needed</td>
</tr>
<tr>
<td>surfactant</td>
<td>as needed</td>
</tr>
<tr>
<td>purified water</td>
<td>to make 100%</td>
</tr>
</tbody>
</table>

The actual dose of the active compounds of the present invention depends on the specific compound, and on the condition to be treated; the selection of the appropriate dose is well within the knowledge of the skilled artisan.

The ophthalmic formulations of the present invention are conveniently packaged in forms suitable for metered application, such as in containers equipped with a dropper, to facilitate application to the eye. Containers suitable for drop wise application are usually made of suitable inert, non-toxic plastic material, and generally contain between about 0.5 and about 15 ml solution. One package may contain one or more unit doses. Especially preservative-free solutions are often formulated in non-resalable containers containing up to about ten, preferably up to about five units doses, where a typical unit dose is from one to about 8 drops, preferably one to about 3 drops. The volume of one drop usually is about 20-35 ml.

Invention compounds may also be administered in the form of suppositories for rectal administration of the drug. These compositions may be prepared by mixing the invention compounds with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters of polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.

Since individual subjects may present a wide variation in severity of symptoms and each drug has its unique therapeutic characteristics, the precise mode of administration and dosage employed for each subject is left to the discretion of the practitioner.
The compounds and pharmaceutical compositions described herein are useful as medicaments in mammals, including humans, for treatment of diseases and/or alleviations of conditions which are responsive to treatment by agonists or functional antagonists of sphingosine-1-phosphate receptors. Thus, in further embodiments of the invention, there are provided methods for treating a disorder associated with modulation of sphingosine-1-phosphate receptors. Such methods can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one invention compound. As used herein, the term "therapeutically effective amount" means the amount of the pharmaceutical composition that will elicit the biological or medical response of a subject in need thereof that is being sought by the researcher, veterinarian, medical doctor or other clinician. In some embodiments, the subject in need thereof is a mammal. In some embodiments, the mammal is human.

The present invention concerns also processes for preparing the compounds of Formula I. The compounds of Formula I according to the invention can be prepared analogously to conventional methods as understood by the person skilled in the art of synthetic organic chemistry. Synthetic Scheme 1, set forth below, illustrates how compounds according to the invention can be made.

**Scheme 1**
General procedure
To a solution of a carboxylic acid in THF at RT was added CDI. After stirring the reaction mixture for 2 h, an appropriate N-hydroxy-4-(hydroxymethyl) benz-imidamide derivative was added. After stirring at 50 °C for 3h, the reaction mixture was then transferred to a microwave vial and heated at 150 °C for 20 minutes. After cooling to room temperature the mixture was diluted with water and extracted with ethyl acetate. The ethyl acetate phase was washed with water and brine, dried over sodium sulfate and concentrated. Purification of the residue by MPLC (40 % ethyl acetate in hexanes) gave the corresponding oxadiazol intermediate. To the intermediate in dichloromethane and acetonitrile were added 4A molecular sieves, powdered NMO, TPAP. After stirring for 16 h, the reaction mixture was applied directly to a short silica gel plug followed by MPLC purification (20 % ethyl acetate in hexanes) to afford the corresponding aldehyde.
The aldehyde intermediate was dissolved in methanol and 3-azetidinecarboxylic acid was added. After the reaction mixture was stirred at RT for 1.5h, sodium triacetoxyborohydride was added. After the mixture was stirred at RT for 3.5h, the mixture was concentrated and purified by MPLC (0-100% methanol in ethyl acetate) to give the desired compound of Formula I.

The following abbreviations are used in the general schemes and in the examples:

- CDI: 1,1'-Carbonyldiimidazole
- MWI: Microwave
- THF: Tetrahydrofuran
- NMO: N-Methylmorpholine-N-Oxide
- TPAP: Tetrapropylammonium perruthenate
- MPLC: Medium pressure liquid chromatography
- MeOH: Methanol
- RT: Room temperature
- CDCl₃: Deuterated chloroform
- CD₂OD: Deuterated methanol
- PPTS: Pyridine p-toluenesulfonate

Those skilled in the art will be able to routinely modify and/or adapt Scheme 1 to synthesize any compound of the invention covered by Formula I.

DETAILED DESCRIPTION OF THE INVENTION

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention claimed. As used herein, the use of the singular includes the plural unless specifically stated otherwise.

It will be readily apparent to those skilled in the art that some of the compounds of the invention may contain one or more asymmetric centers, such that the compounds may exist in enantiomeric as well as in diastereomeric forms. Unless it is specifically noted otherwise, the scope of the present invention includes all enantiomers, diastereomers and racemic mixtures. Some of the compounds of the invention may form salts with pharmaceutically acceptable acids or bases, and such pharmaceutically
acceptable salts of the compounds described herein are also within the scope of the invention.

The present invention includes all pharmaceutically acceptable isotopically enriched compounds. Any compound of the invention may contain one or more isotopic atoms enriched or different than the natural ratio such as deuterium $^2\text{H}$ (or D) in place of protium $^1\text{H}$ (or H) or use of $^{13}\text{C}$ enriched material in place of $^{12}\text{C}$ and the like. Similar substitutions can be employed for N, O and S. The use of isotopes may assist in analytical as well as therapeutic aspects of the invention. For example, use of deuterium may increase the in vivo half-life by altering the metabolism (rate) of the compounds of the invention. These compounds can be prepared in accord with the preparations described by use of isotopically enriched reagents.

The following examples are for illustrative purposes only and are not intended, nor should they be construed as limiting the invention in any manner. Those skilled in the art will appreciate that variations and modifications of the following examples can be made without exceeding the spirit or scope of the invention.

As will be evident to those skilled in the art, individual diastereoisomeric forms can be obtained by separation of mixtures thereof in conventional manner, chromatographic separation may be employed.

Compound names were generated with ACDLabs version 12.5 and intermediates and reagent names used in the examples were generated with software such as Chem Bio Draw Ultra version 12.0 or Auto Norm 2000 from MDL ISIS Draw 2.5 SP1.

In general, characterization of the compounds is performed according to the following methods: NMR spectra are recorded on 300 and/or 600 MHz Varian and acquired at room temperature. Chemical shifts are given in ppm referenced either to internal TMS or to the solvent signal.

All the reagents, solvents, catalysts for which the synthesis is not described are purchased from chemical vendors such as Sigma Aldrich, Fluka, Bio-Blocks, Combi-blocks, TCI, VWR, Lancaster, Oakwood, Trans World Chemical, Alfa, Fisher, AK Scientific, AmFine Com, Carbocore, Maybridge, Frontier, Matrix, Ukrorgsynth, Toronto, Ryan Scientific, SiliCycle, Anaspec, Syn Chem, Chem-Impex, MIC-scientific, Ltd; however some known intermediates, were prepared according to published procedures. Usually the compounds of the invention were purified by column chromatography (Auto-column) on an Teledyne-ISCO CombiFlash with a silica column, unless noted otherwise.
Example 1

**Intermediate 1**

f4-r5-(4-Phenylbutyl)-1,2,4-oxadiazol-3-yl1phenyl)methanol

To a solution of 5-phenylpentanoic acid (370 mg, 2.07 mmol) in THF (10 mL) at RT was added 1,1'-carbonyldiimidazole (337 mg, 2.07 mmol). After stirring the reaction mixture for 2 h, N-hydroxy-4-(hydroxymethyl)benzimidamide (345 mg, 2.07 mmol) was added. After stirring at 50 °C for 3 h, the reaction mixture was then transferred to a microwave vial and heated at 150 °C for 20 minutes. After cooling to room temperature the mixture was diluted with water and extracted with ethyl acetate. Ethyl acetate phase was washed with water and brine, dried over sodium sulfate and concentrated. Purification of the residue by MPLC (40 % ethyl acetate in hexanes) gave 324 mg of Intermediate 1 as colorless oil.

\[ ^1H \text{NMR} (600 \text{ MHz, CDCl}_3) \delta \text{ ppm} \]

8.01 (d, \( J = 8.22 \text{ Hz, 2H} \)), 7.41 (d, \( J = 8.22 \text{ Hz, 2H} \)), 7.26 - 7.31 (m, 2H), 7.17 - 7.21 (m, 3H), 4.68 (s, 2H), 2.92 (t, \( J = 7.63 \text{ Hz, 2H} \)), 2.67 (t, \( J = 7.63 \text{ Hz, 2H} \)), 1.89 (quin, \( J = 7.70 \text{ Hz, 2H} \)), 1.75 (quin, \( J = 7.70 \text{ Hz, 2H} \)).

Example 2

**Intermediate 2**

4-r5-(4-Phenylbutyl)-1,2,4-oxadiazol-3-vnbenzaldehyde

To a solution of Intermediate 1 (787 mg, 2.5 mmol) in dichloromethane (15 mL) and acetonitrile (1.8 mL) were added 4A molecular sieves, powdered (0.5 g), 4-methylmorpholine N-oxide (747 mg, 6.4 mmol), tetrapropylammonium perruthenate (20 mg). After stirring for 16 h, the reaction mixture was applied directly to a short silica gel plug followed by MPLC purification (20 % ethyl acetate in hexanes) to afford 400 mg Intermediate 2 as colorless solid.
\[ ^1\text{H NMR (600 MHz, CDCl}_3 \delta \text{ppm 10.09 (s, 1H), 8.25 (d, } \text{J = 8.22 Hz, 2H), 8.00 (d, } \text{J = 8.22 Hz, 2H), 7.27 - 7.31 (m, 2H), 7.18 - 7.21 (m, 3H), 3.00 (t, } \text{J = 7.48 Hz, 2H), 2.70 (t, } \text{J = 7.63 Hz, 2H), 1.94 (qd, } \text{J = 7.48, 7.68 Hz, 2H), 1.78 (quin, } \text{J = 7.70 Hz, 2H).} \]

Example 3

**Compound 1**

1-(4-r5-(4-Phenylbutyl)-1,2,4-oxadiazol-3-yl1benzyl)azetidine-3-carboxylic acid

To a solution of Intermediate 2 (10.1 mg, 0.33 mmol) in methanol (10 mL) was added 3-azetidinecarboxylic acid ([CAS 36476-78-5] 35 mg, 0.35 mmol). After the reaction mixture was stirred at RT for 1.5h, sodium triacetoxyborohydride (73 mg, 0.34 mmol) was added. After the mixture was stirred at RT for 3.5h, the mixture was concentrated and purified by MPLC (0-100% methanol in ethyl acetate) to give 79 mg of Compound 1 as a colorless solid.

Example 4

**Biological Data**

Compounds were synthesized and tested for S1P1 activity using the GTP \( \gamma^{35}\text{S} \) binding assay. These compounds may be assessed for their ability to activate or block activation of the human S1P1 receptor in cells stably expressing the S1P1 receptor.

GTP \( \gamma^{35}\text{S} \) binding was measured in the medium containing (mM) HEPES 25, pH 7.4, MgCl\(_2\) 10, NaCl 100, dithiothreitol 0.5, digitonin 0.003%, 0.2 nM GTP \( \gamma^{35}\text{S} \), and 5 \( \mu \text{g} \) membrane protein in a volume of 150 \( \mu\text{l} \). Test compounds were included in the concentration range from 0.08 to 5,000 nM unless indicated otherwise. Membranes were incubated with 100 \( \mu\text{M} \) 5'-adenylylimidodiphosphate for 30 min, and
subsequently with 10 μM GDP for 10 min on ice. Drug solutions and membrane were mixed, and then reactions were initiated by adding GTP γ^{35}S and continued for 30 min at 25 °C. Reaction mixtures were filtered over Whatman GF/B filters under vacuum, and washed three times with 3 mL of ice-cold buffer (HEPES 25, pH7.4, MgCl₂ 10 and NaCl 100). Filters were dried and mixed with scintillant, and counted for ^{35}S activity using a β-counter. Agonist-induced GTP γ^{35}S binding was obtained by subtracting that in the absence of agonist. Binding data were analyzed using a non-linear regression method. In case of antagonist assay, the reaction mixture contained 10 nM S₁P₁ in the presence of test antagonist at concentrations ranging from 0.08 to 5000 nM. Table 1 shows activity potency: S₁P₁ receptor from GTP γ^{35}S: nM, (EC₅₀).

<table>
<thead>
<tr>
<th>IUPAC name</th>
<th>S₁P₁ EC₅₀ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-{[4-][5-(4-phenylbutyl)]-1,2,4-oxadiazol-3-yl]benzyl}azetidine-3-carboxylic acid</td>
<td>483.13</td>
</tr>
</tbody>
</table>
What is claimed is:

1. A compound represented by Formula I, its individual enantiomers, individual diastereoisomers, individual tautomers or a pharmaceutically acceptable salt thereof

![Chemical Structure](image)

**Formula I**

wherein:
- \( R^1 \) is substituted or unsubstituted \( C_{6-10} \) aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted \( C_{5-8} \) cycloalkyl, substituted or unsubstituted \( C_{5-8} \) cycloalkenyl or hydrogen;
- \( R^2 \) is hydrogen, \(-OC\)\(_3\) alkyl or substituted or unsubstituted \( C_{1-3} \) alkyl;
- \( R^3 \) is hydrogen, halogen, substituted or unsubstituted \( C_{1-3} \) alkyl, \( C(0)R^7 \) or hydroxyl;
- \( R^4 \) is hydrogen, halogen, substituted or unsubstituted \( C_{1-3} \) alkyl, \( C(0)R^7 \) or hydroxyl;
- \( R^5 \) is hydrogen, halogen, substituted or unsubstituted \( C_{1-3} \) alkyl, \( C(0)R^7 \), hydroxyl or substituted or unsubstituted heterocycle;
- \( R^6 \) is hydrogen, halogen, substituted or unsubstituted \( C_{1-3} \) alkyl, \( C(0)R^7 \), hydroxyl or substituted or unsubstituted heterocycle;
- \( R^7 \) is hydrogen, \(-OR^8 \) or substituted or unsubstituted \( C_{1-3} \) alkyl;
- \( R^8 \) is H or \( C_{1-3} \) alkyl;
- \( a \) is 2 or 3;
- \( b \) is 1, 2 or 3; and
- \( c \) is 1, 2, 3, 4, 5 or 6.
2. A compound according to claim 1 which is 1-{4-[5-(4-Phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}azetidine-3-carboxylic acid.

3. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable adjuvant, diluent or carrier.

4. A pharmaceutical composition according to claim 3 wherein the compound is 1-{4-[5-(4-Phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}azetidine-3-carboxylic acid.

5. A method of treating a disorder associated with sphingosine-1-phosphate receptor modulation, which comprises administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I:

\[
\text{Formula I}
\]

wherein:

- \( R^1 \) is substituted or unsubstituted \( C_6 \)-aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted \( C_5 \)-8 cycloalkyl, substituted or unsubstituted \( C_5 \)-8 cycloalkenyl or hydrogen;
- \( R^2 \) is hydrogen, -OCi-3 alkyl or substituted or unsubstituted \( C_{1-3} \) alkyl;
- \( R^3 \) is hydrogen, halogen, substituted or unsubstituted \( C_{1-3} \) alkyl, C(0)R or hydroxyl;
- \( R^4 \) is hydrogen, halogen, substituted or unsubstituted \( C_{1-3} \) alkyl, C(0)R or hydroxyl;
- \( R^5 \) is hydrogen, halogen, substituted or unsubstituted \( C_{1-3} \) alkyl, C(0)R, hydroxyl or substituted or unsubstituted heterocycle;
6. A method of claim 5, wherein the pharmaceutical composition is administered to the mammal to treat ocular diseases, wet and dry age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, retinal edema, geographic atrophy, glaucomatous optic neuropathy, chorioretinopathy, hypertensive retinopathy, ocular ischemic syndrome, prevention of inflammation-induced fibrosis in the back of the eye, various ocular inflammatory diseases including uveitis, scleritis, keratitis, and retinal vasculitis; or systemic vascular barrier related diseases, various inflammatory diseases, including acute lung injury, its prevention, sepsis, tumor metastasis, atherosclerosis, pulmonary edemas, and ventilation-induced lung injury; or autoimmune diseases and immunosuppression, rheumatoid arthritis, Crohn's disease, Graves' disease, inflammatory bowel disease, multiple sclerosis, Myasthenia gravis, Psoriasis, ulcerative colitis, antoimmune uveitis, renal ischemia perfusion injury, contact hypersensitivity, atopic dermatitis, and organ transplantation; or allergies and other inflammatory diseases, urticaria, bronchial asthma, and other airway inflammations including pulmonary emphysema and chronic obstructive pulmonary diseases; or cardiac protection, ischemia reperfusion injury and atherosclerosis; or wound healing such as but not limited to: scar-free healing of wounds from cosmetic skin surgery, ocular surgery, GI surgery, general surgery, oral injuries, various mechanical, heat and burn injuries, prevention and treatment of photoaging and skin ageing, and prevention of radiation-induced injuries; or bone formation, treatment of osteoporosis and various bone fractures including hip and ankles; or anti-nociceptive activity, visceral pain, pain associated with diabetic neuropathy, rheumatoid arthritis, chronic knee and joint pain, tendonitis, osteoarthritis, neuropathic pains; or central nervous system neuronal activity in Alzheimer's disease, age-related neuronal injuries; or organ transplant such as renal, corneal, cardiac or adipose tissue transplant.
7. The method of claim 6 wherein the mammal is a human.
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

According to International Patent Classification (IPC) into both national classification and IPC:

<table>
<thead>
<tr>
<th>Inv.</th>
<th>C07D413/10</th>
<th>A61K31/416</th>
<th>A61P3/04</th>
</tr>
</thead>
</table>

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols):

- C07D
- A61K
- A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):

- EPO-Internal
- BIOSIS
- CHEM ABS Data
- EMBASE
- WPI Data
- BEILSTEIN Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>wo 2012/012477 AI (SQUIBB BRISTOL MYERS CO [US]; DAS JAGABANDHU [US]; K0 S00 SUNG [US]; S) 26 January 2012 (2012-01-26) page 40; claims; examples 98, 102, 126</td>
<td>1-7</td>
</tr>
<tr>
<td>X</td>
<td>wo 2010/043000 AI (AKAAL PHARMA PTY LTD [AU]; GI LL GURMIT S [AU]; GROBELNY DAMIAN W [AU]) 22 April 2010 (2010-04-22) claims</td>
<td>1-7</td>
</tr>
<tr>
<td>A</td>
<td>wo 2010/085581 AI (SQUIBB BRISTOL MYERS CO [US]; WATTERSON SCOTT HUNTER [US]; DYCKMAN ALA) 29 July 2010 (2010-07-29) page 139 - page 143; claim 1</td>
<td>1-7</td>
</tr>
<tr>
<td>A</td>
<td>wo 03/105771 A2 (MERCK &amp; CO INC [US]; CHEN WEI RONG [US]; HALE JEFFREY J [US]; LI ZHEN [C]) 24 December 2003 (2003-12-24) claims; examples</td>
<td>1-7</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

- Special categories of cited documents:
  - "A" document defining the general state of the art which is not considered to be of particular relevance
  - "E" earlier application or patent but published on or after the international filing date
  - "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  - "O" document referring to an oral disclosure, use, exhibition or other means
  - "P" document published prior to the international filing date but later than the priority date claimed
  - "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  - "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  - "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is considered in combination with one or more other such documents, such combination being obvious to a person skilled in the art
  - "A" document member of the same patent family

**Date of the actual completion of the international search**

25 October 2013

**Date of mailing of the international search report**

04/11/2013

**Name and mailing address of the ISA**

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

**Authorized officer**

Hartinger, Stefan

Form PCT/ISA210 (second sheet) (April 2005)
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>wo 2012012477 Al 26-01-2012</td>
<td>CN 103124727 A</td>
<td>29-05-2013</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EP 2595969 Al</td>
<td>29-05-2013</td>
<td></td>
</tr>
<tr>
<td></td>
<td>JP 2013531070 A</td>
<td>01-08-2013</td>
<td></td>
</tr>
<tr>
<td></td>
<td>US 2013158001 Al</td>
<td>20-06-2013</td>
<td></td>
</tr>
<tr>
<td></td>
<td>WO 2012012477 Al</td>
<td>26-01-2012</td>
<td></td>
</tr>
<tr>
<td>wo 2010043000 Al 22-04-2010</td>
<td>AU 2009304598 Al</td>
<td>22-04-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CA 2740484 Al</td>
<td>22-04-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CN 102186845 A</td>
<td>14-09-2011</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EP 2344484 Al</td>
<td>20-07-2011</td>
<td></td>
</tr>
<tr>
<td></td>
<td>JP 2012505836 A</td>
<td>08-03-2012</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NZ 592748 A</td>
<td>25-01-2013</td>
<td></td>
</tr>
<tr>
<td></td>
<td>US 2011318388 Al</td>
<td>29-12-2011</td>
<td></td>
</tr>
<tr>
<td></td>
<td>WO 2010043000 Al</td>
<td>22-04-2010</td>
<td></td>
</tr>
<tr>
<td>wo 2010085581 Al 29-07-2010</td>
<td>CN 102361867 A</td>
<td>22-02-2012</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EP 2382212 Al</td>
<td>02-11-2011</td>
<td></td>
</tr>
<tr>
<td></td>
<td>JP 2012515787 A</td>
<td>12-07-2012</td>
<td></td>
</tr>
<tr>
<td></td>
<td>US 2011300165 Al</td>
<td>08-12-2011</td>
<td></td>
</tr>
<tr>
<td></td>
<td>WO 2010085581 Al</td>
<td>29-07-2010</td>
<td></td>
</tr>
<tr>
<td>wo 03105771 A2 24-12-2003</td>
<td>AU 2003276043 Al</td>
<td>31-12-2003</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CA 2488117 Al</td>
<td>24-12-2003</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EP 1549640 A2</td>
<td>06-07-2005</td>
<td></td>
</tr>
<tr>
<td></td>
<td>JP 2005533058 A</td>
<td>04-11-2005</td>
<td></td>
</tr>
<tr>
<td></td>
<td>US 2005245575 Al</td>
<td>03-11-2005</td>
<td></td>
</tr>
<tr>
<td></td>
<td>WO 03105771 A2</td>
<td>24-12-2003</td>
<td></td>
</tr>
</tbody>
</table>